GLP-1 receptor agonists are among the most expensive medications in common use, with monthly costs ranging from $800 to $1,400 without insurance. Insurance coverage is critical for most patients — but initial prior authorization (PA) denials are the norm, not the exception. Understanding the system and knowing how to navigate it effectively can mean the difference between starting treatment in weeks or not at all.
This guide covers the prior authorization landscape, insurer-specific criteria, the appeal process, ICD-10 coding requirements, and manufacturer patient assistance programs — everything a patient or prescriber needs to maximize the chances of coverage approval.
Why GLP-1 Prior Authorizations Get Denied
Prior authorization denials for GLP-1 agonists fall into several predictable categories. Understanding the actual reason for denial is the first step to a successful appeal. The most common denial reasons are:
- Step therapy not completed: Many plans require documented failure of cheaper alternatives (metformin, phentermine, orlistat) before approving GLP-1 drugs.
- BMI threshold not met: Plans may require BMI ≥30, or BMI ≥27 with specific comorbidities, and require this to be documented in chart notes — not just the PA form.
- Missing comorbidity documentation: The ICD-10 code for the relevant comorbidity (T2D, HTN, hyperlipidemia) must appear on the claim — it is not sufficient for the prescriber to be aware of it without coding it.
- Drug not on formulary for obesity indication: Ozempic is often on formulary for T2D but denied for obesity; Wegovy may be excluded from the formulary entirely under some employer-sponsored plans.
- Missing dietary counseling documentation: Some plans require a documented 3–6 month supervised weight loss program prior to GLP-1 authorization.
The Evidence on PA Denial Rates and Appeal Success
IQVIA Institute: 66% of Initial GLP-1 PAs Denied by Commercial Insurers
Analysis of commercial insurance claims data found that approximately 66% of initial prior authorization requests for GLP-1 receptor agonists for obesity indications were denied on the first submission. Denials were more common for Wegovy (Novo Nordisk) compared to Ozempic used off-label for obesity, suggesting formulary position and benefit category play significant roles. The report found that denial rates varied markedly by insurer type: self-funded employer plans had the highest denial rates (72%), while fully-insured commercial plans had lower rates (~58%). State-regulated individual market plans had the lowest denial rates (~44%).
Aetna Coverage Criteria: What Must Be Documented
Aetna's clinical policy for anti-obesity medications requires: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease). Documentation of a supervised weight management program of at least 6 months duration within the past 2 years is required. The prescriber must be the patient's treating physician (not a telehealth-only provider in some plan iterations). A BMI measurement must appear in chart notes within 6 months of the PA request. Crucially, Aetna will deny the claim if the ICD-10 obesity code (E66.01 or E66.09) does not appear on the prescription claim — even if BMI is adequately documented elsewhere.
Medicare Part D Now Covers Wegovy for Cardiovascular Indication
The Inflation Reduction Act and subsequent CMS guidance expanded Medicare Part D coverage to include Wegovy (semaglutide 2.4mg) for patients with obesity and established cardiovascular disease, effective January 2026. This coverage is grounded in the SELECT trial evidence showing a 20% MACE reduction. However, coverage is explicitly tied to the cardiovascular indication — Medicare Part D does not cover GLP-1 agonists for weight loss alone without the CV comorbidity. Patients without established CVD but with obesity and other comorbidities may not qualify under this provision. Advocates continue to push for broader Medicare obesity drug coverage under pending legislation.
Step Therapy Requirements Add 4.7 Months Average Delay
An analysis of insurance claims data and patient surveys found that step therapy requirements — mandatory trials of cheaper first-line agents before GLP-1 authorization — added an average of 4.7 months to treatment initiation for patients who ultimately received GLP-1 therapy. During this period, patients who would benefit from GLP-1 treatment are exposed to less effective interventions with their own side effect profiles (phentermine has cardiac risks; orlistat has significant GI effects), and many patients give up on the appeals process entirely. The analysis estimated that step therapy requirements prevented approximately 28% of clinically eligible patients from ever reaching GLP-1 treatment.
ICD-10 Codes: Get These Right
Coding errors are a leading cause of preventable PA denials. The following ICD-10 codes must appear correctly on both the PA request and any prescription claims:
Key ICD-10 Codes for GLP-1 Coverage
Prior Authorization Success Protocol
Prior Authorization Success Protocol
- Step 1 — Document BMI in chart notes: Ensure current BMI is measured and recorded in the clinical note within the last 3–6 months. The number must appear in the chart — "overweight" or "obese" alone is insufficient for most plans. Include height, weight, and calculated BMI.
- Step 2 — Ensure all comorbidities are correctly coded: Review the patient's problem list. Every relevant comorbidity (HTN, T2D, hyperlipidemia, sleep apnea) must be an active diagnosis with a current ICD-10 code on the chart. If conditions are present but not formally coded, add them before submitting the PA.
- Step 3 — Document prior weight loss attempts: Include documentation of dietary counseling, supervised programs, or prior pharmacotherapy trials. Even informal records of program participation help. Some plans require a formal 3–6 month documented program.
- Step 4 — Submit the PA with clinical notes attached: Do not submit PA forms alone — attach the relevant clinical notes showing BMI, comorbidities, and dietary counseling history. Insurers can only approve what is documented.
- Step 5 — Request peer-to-peer review immediately upon denial: When a PA is denied, immediately request a peer-to-peer (P2P) review — a phone call between your prescriber and the insurer's medical reviewer. P2P reviews overturn denials approximately 40–60% of the time. This must be requested within the insurer's timeframe (often 5–10 business days of denial).
- Step 6 — File a formal appeal with trial evidence: If P2P fails, file a formal written appeal. Attach the SELECT trial reprint (for semaglutide), STEP 1 trial abstract, and SCALE trial data. Cite the clinical practice guidelines from the Obesity Medicine Association (OMA) and AACE recommending GLP-1 agonists as first-line pharmacotherapy.
- Step 7 — If denied twice, apply for manufacturer PAP: Novo Nordisk NovoCare (1-833-NOVO-411) and Eli Lilly LillyAnswers (1-800-545-5979) offer patient assistance programs for income-eligible patients. Eligibility criteria vary but typically include income ≤400–600% of the federal poverty level and no other coverage.
Sample Appeal Letter Template
The following template can be adapted by prescribers or patients for a formal written appeal. Fill in bracketed fields with specific patient information and insurer details.
Major Insurer Coverage Comparison
| Insurer | Wegovy Covered | Ozempic (Off-label obesity) | BMI Threshold | Required Comorbidities | Step Therapy Required | PA Approval Rate (est.) |
|---|---|---|---|---|---|---|
| Aetna | Yes (commercial) | No (T2D indication only) | ≥30 or ≥27+comorbidity | T2D, HTN, dyslipidemia, OSA, or CVD | Yes — 6-month program | ~38% |
| BCBS (varies by plan) | Varies by state/plan | Rarely | ≥30 or ≥27+comorbidity | At least 1 comorbidity | Often yes (3–6 months) | ~30–45% |
| UnitedHealthcare | Some commercial plans | No | ≥30 or ≥27+comorbidity | T2D, HTN, or CVD | Yes — documented program | ~32% |
| Cigna | Yes (most commercial) | T2D only | ≥30 | Preferred but not always required | Varies by employer plan | ~40% |
| Medicare Part D | Yes — obesity + CVD only (Jan 2026) | T2D only | ≥30 + CVD diagnosis | Established CVD required (SELECT basis) | Yes — varies by plan | ~45% (CVD indication) |
| Medicaid (state varies) | Rare — most state Medicaid plans exclude | T2D only in most states | N/A (largely excluded) | T2D required in most states | N/A | <15% (obesity only) |
Insurer policies change frequently. The criteria above reflect publicly available policy documents as of 2024; always verify current criteria directly with the insurer or through your prescriber's prior authorization team before submitting. Employer-sponsored self-funded plans may have entirely different criteria than the insurer's standard commercial policy.
Manufacturer Patient Assistance Programs
When insurance coverage fails, both Novo Nordisk and Eli Lilly maintain patient assistance programs that can provide free or deeply discounted medication for eligible patients:
- Novo Nordisk NovoCare (Wegovy, Ozempic, Saxenda): Available to US residents with no insurance or inadequate insurance coverage. Income requirements apply (typically ≤400% federal poverty level). Call 1-833-NOVO-411 or visit novonordisk-us.com/patients/novocare.html
- Eli Lilly LillyAnswers (Zepbound, Mounjaro): For commercially insured patients, Lilly offers a savings card reducing Zepbound to ~$550/month. For uninsured patients, LillyAnswers can reduce cost to $35/month for eligible individuals. Visit lilly.com/assistance or call 1-800-545-5979
- Compounded semaglutide: 503B outsourcing facilities legally produced compounded semaglutide during FDA shortage periods at significantly lower cost (~$100–300/month). The FDA shortage designation for semaglutide ended in early 2025, which may affect compounding availability — check current FDA shortage status at accessdata.fda.gov/scripts/drugshortages